05
May

The battering that AcelRx has been subjected to on Wall Street won’t stop. The biotech announced that the FDA won’t even sit down to discuss regulators’ demand for a new clinical trial to assess the efficacy of its pain drug/device Zalviso. And increasingly skeptical investors weighed in on the biotech’s most recent setback by pummeling shares once again.

…read more

Source: AcelRx takes a fresh beating as the FDA turns a cold shoulder on Zalviso

    

0 No comments